Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade.

Cancer research - 15 Nov 2018

Wang Zhijie, Zhao Jing, Wang Guoqiang, Zhang Fan, Zhang Zemin, Zhang Fan, Zhang Yuzi, Dong Hua, Zhao Xiaochen, Duan Jianchun, Bai Hua, Tian Yanhua, Wan Rui, Han Miao, Cao Yan, Xiong Lei, Liu Li, Wang Shuhang, Cai Shangli, Mok Tony S K, Wang Jie

Abstract excerpt

Biomarkers such as programmed death receptor 1 ligand (PD-L1) expression, tumor mutational burden (TMB), and high microsatellite instability are potentially applicable to predict the efficacy of immune checkpoint blockade (ICB). However, several challenges such as defining the cut-off value, test platform uniformity, and low frequencies limit their broad clinical application. Here we identify comutations in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mismatch Repair

Share to Homologous Recombination

Share to Immune System

Share to Immunophenotyping

Share to Microsatellite Instability

Share to Tumor Burden

Source

Identifiers

PMID: 30171052
DOI: 10.1158/0008-5472.CAN-18-1814

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade.PMID 30171052Read ↗

Diverse immune response of DNA damage repair-deficient tumors.Semantic proximity Read ↗

DNA Damage and Repair Biomarkers of Immunotherapy ResponseSemantic proximity Read ↗

Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor ImmunotherapySemantic proximity Read ↗

Predicting response to immune checkpoint blockade therapy among mismatch repair-deficient patients using mutational signaturesSemantic proximity Read ↗

Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy.Semantic proximity Read ↗

Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a MatchmakerSemantic proximity Read ↗

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers.Semantic proximity Read ↗

Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor typesSemantic proximity Read ↗

Role of DNA repair defects in predicting immunotherapy responseSemantic proximity Read ↗

Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations.Semantic proximity Read ↗

Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.Semantic proximity Read ↗

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.